Market Research Industry Reports

Retrophin Inc (RTRX) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Retrophin Inc (Retrophin) is a biopharmaceutical company that discovers, develops, acquires and commercializes drugs for the treatment of rare diseases. The companys products include thiola, chenodal and cholbam. It develops drugs for various catastrophic diseases. Retrophins pipeline products include sparsentan, used for the treatment of focal segmental glomerulosclerosis; RE-024, a product candidate to treat pantothenate kinase-associated neurodegeneration and RE-034, utilized for the treatment of severe rare diseases. The company markets its products through its distribution partners. It works in partnership with academia and independent researchers to support the development of novel solutions. The company operates in New York and Massachusetts, the US. Retrophin is headquartered in San Diego, California, the US.

Retrophin Inc (RTRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Retrophin Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Retrophin Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Retrophin Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Retrophin Acquires Liquid Formulation of Ursodeoxycholic Acid from Asklepion Pharma 12
Retrophin Acquires Cholic Acid Rights from Asklepion Pharma 13
Venture Financing 14
Perlstein Lab Raises USD2 Million in Seed Financing 14
Retrophin Raises US$4 Million In Series A Financing 15
Partnerships 16
Retrophin Enters into Agreement with Censa Pharma 16
Retrophin Enters into Research Agreement with National Center for Advancing Translational Sciences and NGLY1 17
Retrophin Enters into Research Agreement with Grace Wilsey Foundation and Warren Family Research Center 18
Licensing Agreements 19
Retrophin Amends Licensing Agreement with Mission Pharmacal for Thiola 19
Retrophin Enters Into Licensing Agreement With Novartis Pharma For Syntocinon Nasal Spray 20
Retrophin Enters Into Licensing Agreement To Develop Product For Autism And Schizophrenia Treatment 21
Ligand Pharma Amends Licensing Agreement with Retrophin 22
Equity Offering 24
Retrophin Raises USD149.4 Million in Public Offering of Shares 24
Retrophin Raises USD40 Million in Public Offering of Shares 25
Retrophin Completes Private Placement Of Shares For US$25 Million 27
Retrophin Announces Private Placement Of Common Stock For US$10 Million 28
Debt Offering 29
Retrophin Raises USD40 Million in Private Placement of Notes Due 2019 29
Asset Transactions 30
Sanofi Acquires Rights to Pediatric PRV from Retrophin for USD245 Million 30
Turing Pharma Acquires Vecamyl, Syntocinon and ketamine from Retrophin 31
Acquisition 33
Retrophin to Acquire Clinuvel Pharma 33
Retrophin Completes Acquisition Of Manchester Pharma For US$62.5 Million 35
Retrophin Acquires Kyalin Biosciences for USD5 Million 36
Desert Gateway Completes Acquisition Of Retrophin In Reverse Takeover Transaction 37
Retrophin Inc - Key Competitors 38
Retrophin Inc - Key Employees 39
Retrophin Inc - Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 42
Financial Announcements 42
May 01, 2018: Retrophin Announces First Quarter 2018 Financial Results 42
Feb 27, 2018: Retrophin Reports Fourth Quarter and Full Year 2017 Financial Results 44
Nov 07, 2017: Retrophin Reports Third Quarter 2017 Financial Results 46
Aug 09, 2017: Retrophin Reports Second Quarter 2017 Financial Results 48
May 04, 2017: Retrophin Reports First Quarter 2017 Financial Results 50
Mar 01, 2017: Retrophin Reports Fourth Quarter and Full Year 2016 Financial Results 51
Jan 09, 2017: Retrophin Provides Corporate Update and 2017 Preview 53
Corporate Communications 54
Aug 14, 2017: Retrophin Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 54
Apr 12, 2017: Retrophin Appoints Ron Squarer to Board of Directors 55
Mar 23, 2017: John A. Orwin Joins Retrophin Board of Directors 56
Feb 13, 2017: Retrophin Appoints William Rote Senior Vice President, Research and Development 57
Legal and Regulatory 58
Aug 04, 2017: Former Hedge Fund Manager Convicted In Multi-Million Dollar Fraud Scheme 58
Clinical Trials 59
May 25, 2017: Retrophin Announces Presentations On Late-Stage Clinical Development Program Sparsentan at Upcoming Medical Congress 59
Mar 01, 2017: Retrophin Provides Sparsentan Regulatory Update 60
Other Significant Developments 61
Jan 08, 2018: Retrophin Provides Corporate Update and 2018 Outlook 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List Of Tables

List of Tables
Retrophin Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Retrophin Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Retrophin Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Retrophin Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Retrophin Acquires Liquid Formulation of Ursodeoxycholic Acid from Asklepion Pharma 12
Retrophin Acquires Cholic Acid Rights from Asklepion Pharma 13
Perlstein Lab Raises USD2 Million in Seed Financing 14
Retrophin Raises US$4 Million In Series A Financing 15
Retrophin Enters into Agreement with Censa Pharma 16
Retrophin Enters into Research Agreement with National Center for Advancing Translational Sciences and NGLY1 17
Retrophin Enters into Research Agreement with Grace Wilsey Foundation and Warren Family Research Center 18
Retrophin Amends Licensing Agreement with Mission Pharmacal for Thiola 19
Retrophin Enters Into Licensing Agreement With Novartis Pharma For Syntocinon Nasal Spray 20
Retrophin Enters Into Licensing Agreement To Develop Product For Autism And Schizophrenia Treatment 21
Ligand Pharma Amends Licensing Agreement with Retrophin 22
Retrophin Raises USD149.4 Million in Public Offering of Shares 24
Retrophin Raises USD40 Million in Public Offering of Shares 25
Retrophin Completes Private Placement Of Shares For US$25 Million 27
Retrophin Announces Private Placement Of Common Stock For US$10 Million 28
Retrophin Raises USD40 Million in Private Placement of Notes Due 2019 29
Sanofi Acquires Rights to Pediatric PRV from Retrophin for USD245 Million 30
Turing Pharma Acquires Vecamyl, Syntocinon and ketamine from Retrophin 31
Retrophin to Acquire Clinuvel Pharma 33
Retrophin Completes Acquisition Of Manchester Pharma For US$62.5 Million 35
Retrophin Acquires Kyalin Biosciences for USD5 Million 36
Desert Gateway Completes Acquisition Of Retrophin In Reverse Takeover Transaction 37
Retrophin Inc, Key Competitors 38
Retrophin Inc, Key Employees 39
Retrophin Inc, Other Locations 40
Retrophin Inc, Subsidiaries 40

List Of Figures

List of Figures
Retrophin Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Retrophin Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Retrophin Inc (RTRX) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Retrophin Inc (Retrophin) is a biopharmaceutical company that discovers, develops, acquires and commercializes drugs for the treatment of rare diseases. The companys products include thiola, chenodal and cholbam. It develops

USD 250View Report

Retrophin Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Retrophin Inc Company Profile is a detailed strategic and analytical report on Retrophin Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200View Report

Retrophin Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Retrophin Inc Company Profile is a detailed strategic and analytical report on Retrophin Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200View Report

Retrophin Inc (RTRX) - Financial and Strategic SWOT Analysis Review

Retrophin Inc (RTRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData

USD 125View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Jul 2018
No. of Pages :62
Country :United States of America
Category :Company Profiles
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube